{'fraction_non_alphanumeric': 0.026402640264026403, 'fraction_numerical': 0.01155115511551155, 'mean_word_length': 5.417989417989418, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Neurophysiological study of 36 patients with cerebral vascular processes treated with nicergoline (author's transl)].

The results obtained from a group of 36 patients with non-acute cerebral vascular disturbances of various forms were evaluated. The clinical course and additional examinations are reported: electroencephalography, visually evoked potentials and cerebral rheography for the assessment of different cerebral regions and an interhemispherical comparison. The determination of the data obtained by rheography can be applied to the whole patient group. All tests were carried out before treatment and after a period of treatment with 15-20 mg 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) administered daily p.o. On the basis of the therapeutic results conclusions can be drawn as to clinical improvement and EEG normalisation and visually evoked potentials. The changes in the amplitude and the changes in the systolic gradient recorded by the rheogramme as well as the tendency to correction of dyssymmetry can be described as the result of nicergoline on the cerebral vascular system, on the oxygen supply and on the metabolism of the brain tissue.